Highlights

  • Biome Australia has signed a binding commercial Manufacturing agreement with Specialty Probiotics Australia (SPA) to progressively transition Activated Probiotics production onshore, with the first batch targeted for September 2026.
  • The agreement requires no upfront Capital Expenditure from Biome and is expected to progressively lift gross margins from the current approximately 61% to 65%+ over the next 18 months.
  • Working Capital benefits from lower inventory days, faster stock turn, and elimination of extended international sea freight are expected alongside the Margin improvements.

 

Biome Australia Limited (ASX:BIO) surged 20.00% on 3 June 2026 to trade at A$0.27, as the company announced it had signed a commercial manufacturing agreement with Specialty Probiotics Australia (SPA) — a domestic GMP-licensed probiotic manufacturer. The announcement marks the execution of Phase One of Biome's Vision 27 strategic plan and addresses a Supply chain structure that the company has been examining for more than two years.

Biome Australia is the producer and distributor of the Activated Probiotics Brand, a premium probiotic range sold in Australia and increasingly in international markets. The company holds B Corporation certification, a globally recognised standard for social and environmental performance. Since launching the Activated Probiotics range in 2019, Biome has maintained product pricing without a single retail price increase — a commercial discipline that makes the gross margin expansion enabled by onshore manufacturing particularly significant.

The Manufacturing Agreement: Terms and Structure

The agreement with SPA is binding and does not require Biome to make any upfront Capital Investment. SPA is led by Craig Silbery, co-founder and former Chief Executive Officer of Life Space — one of Australia's most commercially successful probiotic companies. The engagement of someone with Silbery's background in probiotic manufacturing and commercialisation brings immediate technical credibility to the Partnership.

Under the agreement, production of the Activated Probiotics range will transition progressively to Australian manufacturing in smaller, more frequent batches — a structural change from the current model of larger, less frequent offshore production runs. The first commercial batch is targeted for September 2026, with the full range expected to transition over approximately 18 months, subject to successful commercial scale-up.

Gross Margin Impact: From 61% Toward 65%+

Biome's current gross margin of approximately 61% is described by management as already at a level that reflects well for a product brand in the consumer health segment. The CFO, Lauren Dwyer, has indicated that onshore manufacturing is expected to progressively lift this margin to 65%+ over the 18-month transition period, commencing from the very first commercial batch.

The margin expansion is driven by several factors. Domestic production eliminates the extended international freight cost component currently embedded in each batch. Smaller, more frequent production runs reduce the buffer stock required, decreasing the working capital held in inventory. Australian manufacturing also avoids duties and Import-related logistics costs that would otherwise be incurred under the current offshore production model.

Working Capital Benefits

Beyond the margin improvement, the transition to onshore manufacturing is expected to deliver a meaningful improvement in Biome's working capital position. The current model, which sources product from European manufacturing partners, involves extended sea freight lead times that tie up capital in transit and require larger batch orders to manage supply chain risk. Producing domestically in smaller batches improves stock turn, reduces the inventory held at any one time, and improves the usable shelf life of finished product before it reaches customers — all of which reduce the capital locked in the supply chain.

Importantly, the agreement requires no capital expenditure from Biome. The capital investment in manufacturing equipment and facilities sits with SPA, not with Biome. This structure allows the company to capture the economic benefits of domestic manufacturing without diluting its Balance Sheet or allocating capital away from sales, Marketing, and product development.

Supply Chain Diversification and B Corp Alignment

Biome will retain its existing European manufacturing partnerships to continue servicing EU markets. This parallel supply chain structure provides diversification and optionality — if one supply source faces disruption, the other remains operational. The retention of European production also ensures Biome does not need to rebuild regulatory and quality approvals for EU market supply from scratch.

The transition to Australian manufacturing reduces the international freight carbon footprint associated with the supply chain, which is relevant to Biome's B Corporation commitments. For a brand positioning around health and quality, "Australian made" provides a differentiated product attribute in export markets where origin and manufacturing standards are increasingly important purchasing considerations.

Vision 27: The Broader Strategic Context

Biome's founder and CEO, Blair Vega Norfolk, has described the SPA agreement as Phase One of the company's Vision 27 strategy to take greater control of its supply chain, manufacturing inputs, and product intellectual property. The language of "phase one" implies a multi-step programme that could include further manufacturing agreements, product IP development, or contract manufacturing capabilities beyond the current range. The strategic intent is to progressively internalise more of the value chain that currently sits with external partners.

Conclusion

Biome Australia's manufacturing partnership with SPA is a structurally significant development for a company at this stage of its growth cycle. The combination of margin expansion from 61% toward 65%+, working capital improvement through smaller domestic batches, and zero capital expenditure required from Biome is an unusually favourable risk-reward structure for a strategic supply chain transition. The 20% share price move on announcement reflects the market's recognition that this is not an incremental operational change but a foundational shift in the company's unit Economics — one that, if executed to plan, will be visible in gross margin progression over the next four to six reporting periods.